Inspyr Therapeutics Inc (OTCMKTS: NSPX) has been treading in recent days since the recent one-for-thirty (1-for-30) reverse stock split of the Common Stock. The ticker symbol is temporarily NSPXD however the stock will be trading as NSPX again soon enough.
Speculators are paying attention to the NSPX (D) story as this one saw 1000% run back in April and not only does NSPXD have a history of explosive moves the Company has strategically expanded its valuable patent portfolio to include 15 issued U.S. patents and more than 40 pending applications worldwide, focused on the U.S., Europe, and Asia Pacific.
Inspyr Therapeutics Inc (OTCMKTS: NSPX) develops curative cancer therapies that are core to the principles of finding the best way to cure or extend human life. Its innovative approach to drug delivery is expected to maximize anti-tumor activity while minimizing side effects. Inspyr’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of the company’s drug candidates within a tumor. Inspyr’s lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the blood vessels of liver and glioblastoma cancers and in the blood vessels of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.
According to the 10k filed in May “We are a clinical-stage, pre-revenue, pharmaceutical company primarily focused on the development of therapeutics for the treatment of diseases. Through our acquisition of Lewis and Clark Pharmaceuticals, Inc., we currently are focusing on a pipeline of small molecule adenosine receptor modulators. The adenosine receptor modulators include A2B antagonists, dual A2A/A2B antagonists, and A2A agonists that have broad development applicability including indications within immuno-oncology and inflammation. Adenosine is implicated in immunosuppression in the tumor microenvironment. Adenosine receptor antagonists may boost the host immune response against the tumor as a single-agent and in combination with other existing immuno-oncology agents leading to enhanced tumor killing and inhibition of metastasis. Adenosine also has anti-inflammatory properties in the acute and chronic setting. Adenosine receptor agonists may promote a decreased inflammatory response and can potentially treat a broad range of inflammatory and autoimmune based diseases and conditions (e.g., rheumatoid arthritis, joint injury, Crohn’s disease, psoriasis) as well as improve wound healing and decrease pain. “
As far as the RS goes NSPX (D) has been there before:
To Find out the inside Scoop on NSPX (D) Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
“We have what we believe to be a robust intellectual property portfolio covering proprietary A2A agonists (LNC-001, see below), A2B antagonists (LNC-002, see below), and dual A2A/A2B antagonists (LNC-003, see below). We also have a substantial catalog of synthesized compounds, specifically A2A agonists and A2B antagonists that require further characterization and testing for potential clinical candidates. We believe that our proprietary dual A2A/A2B antagonists have great potential and should be further explored.”
MicroCapDaily reported on NSPX right before it ran big the last time stating “Inspyr Therapeutics Inc (OTCMKTS: NSPX) is making a big move up the charts since reversing off $0.0015 lows. NSPX has been attracting some power traders in small caps and it’s easy to see why; Mipsagargin, Inspyr lead drug candidate, has been studied in a Phase 2 clinical trial in patients with Nexavar®-refractory hepatocellular carcinoma (HCC) and has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication. The Company recently issued a $250k convertible debenture under favorable terms with a friendly investor.
$NSPXD getting noticed on twitter:
— Jeff (@Jeffritchey) July 1, 2020
We have a Monster Pick Coming. Subscribe Right Now!
NSPX (D) saw 1000% run earlier this year and MicroCapDaily was there right before it happened reporting: NSPX got some more fuel after a press release on Gilead speculated the Company “can prove to be a pivotal player in the race to provide treatments to 100s of millions of people that may require treatment just in the United States alone over the coming months (or maybe years). Their technology and long list of patents may leverage their value to secure partner deal with a top biotech company like Gilead, Roche, and others currently working on treatments and vaccines, or increasing the probability for an outright acquisition of Inspyr. Recently NSPX (D) recently conducted a one-for-thirty (1-for-30) reverse stock split of the Common Stock. The ticker symbol is temporarily NSPXD however the stock will be trading as NSPX again soon enough. Speculators are paying attention to the NSPX (D) story as this one saw 1000% run back in April and not only does NSPXD have a history of explosive moves the Company has strategically expanded its valuable patent portfolio to include 15 issued U.S. patents and more than 40 pending applications worldwide, focused on the U.S., Europe, and Asia Pacific. We will be updating on NSPX when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with NSPX.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in NSPX either long or short and we have not been compensated for this article.